F.S. S i l v e r s t e i n , R. Hutchinson, M.V. Johnston, U.
of Michigan, Depts. of P e d i a t r i c s and Neurology, Ann Arbor. C l i n i c a 1 , r a d i o l o g i c and pathologic evidence of c e n t r a l nervous system(CNS)injury may be found i n c h i l d r e n with ALL who have received CNS prophylaxis with i n t r a t h e c a l ( 1 T ) methotrexate (MTX) & c r a n i o s p i n a l i r r a d i a t i o n . It has been suggested t h a t neuronal s u s c e p t i b i l i t y t o MTX i s due t o i n h i b i t i o n of biogenic aminedopamine(D) & serotonin(S)-synthesis by t h i s drug (Ca Treat Rep 62:1999) .To t e s t t h i s hypothesis, we measured l e v e l s of homovani l l i c acid(HVA) & 5-hydroxyindoleacetic acid(HIAA), s t a b l e a c i d metabolites of D & S , i n weekly s e q u e n t i a l CSF's from 30 p a t i e n t s ( p t s ) with ALL examined prospectively(Group l ) , & i n CSF's from 130 p t s i n remission. Group 1 p t s , 22 boys h 8 g i r l s , age 2-15, with normal pre-treatment HVA and HIAA, received 8 doses of IT MTX a t weekly i n t e r v a l s . Regression a n a l y s i s of HVA l e v e l s revealed a gradual d e c l i n e i n t h e f i r s t 4 wks(r=-1.4)& a more pronounced i n c r e a s e i n t h e next 4 wks(r=+6.5)(p=.027,t-test compari s o n of slopes). Similar t r e n d s were observed f o r HIAA. These changes were independent of age, sex, and CSF p r o t e i n e l e v a t i o n . I n c o n t r a s t , t h e r e was l i t t l e i n t r a -s u b j e c t v a r i a b i l i t y i n l e v e l s i n t h e absence of i n t e n s i v e MTX therapy;60 paired CSF's obtained a t 3 no intervals,showed no changes i n HVA & HIAA. The d a t a provide evidence f o r MTX induced a l t e r a t i o n s i n biogenic amine synt h e s i s and/or t r a n s p o r t . I f t h e l e v e l s r e f l e c t a l t e r e d neuronal a c t i v i t y , these observations may c o n t r i b u t e t o an understanding of changes i n mood, a p p e t i t e , s l e e p , & o t h e r a s p e c t s of behavior which a r e disrupted during treatment.
DDAVP INHIBITS PROSTACYCLIN FORMATION: A POTENTIAL
944 MECHANISM FOR BLEEDING TIME (BT) CORRECTION I N HEMO-STATIC DISORDERS. Marie J. S t u a r t , Carolyn Ganley, Mary Reed, Sherry Boone, Ronald Dubowy, Yamaja S e t t y , SUNY, Ups t a t e Medical Center, Dept. of P e d i a t r i c s , Syracuse, N.Y.
A recent study has shown t h a t DDAVP normalizes t h e B.T. i n p l t . f u n c t i o n a l defects. I n v i t r o evidence a l s o suggests t h a t DDAVP enhances plt-vascular adherence. W e assessed t h e e f f e c t s of DDAVP on prostacyclin a s a p o s s i b l e mediator of these e f f e c t s . I n i t i a l s t u d i e s on human v e s s e l s revealed t h a t incubation of segments with DDAVP . C 6KPGF1, formation. Values of 3.4+0.8 and 2.5+0.7 pmol/mg were obtained i n t h e presence of 0.1 and 1 .0 pg/mi DDAVP, with paired c o n t r o l values of 4 . 1~1 . 0 and 4.021.1 (p<0.01). No d i f f e r e n c e s i n 6KPGF1, were observed when segments were incubated with DDAVP vehicle alone (O.lyg/ml), although a t lpg/ml a s l i g h t + i n 6KPGF1,was seen. Direct assessment of t h e e f f e c t s of DDAVP on ionophore ( l o @ ) stimulated r e l e a s e of 6KPGF1, from bovine endot h e l i a l c e l l monolayers revealed t h a t a t lpg/ml both DDAVP and its v e h i c l e caused a . C i n 6KPGF1, r e l e a s e (33+18 and 31+16 pmol per 106 c e l l s versus c o n t r o l values of 12124E pm01;~<0.?il) . F i n a l l y , changes i n plasma 6KPGFla a r e being assessed i n p a t i e n t s (21.5) with p l t . f u n c t i o n a l d e f e c t s i n whom DDAVP has been used a s a therapeutic modality t o c o r r e c t t h e i r prolonged BTs. A . C i n plasma 6KPGFla has been observed with mean l e v e l s of 0.32 and 0.25 pmol per m l p r i o r t o and 90' post DDAVP respectively. These s t u d i e s , demonstrating an i n v i t r o and i n vivo e f f e c t of DDAVP on e n d o t h e l i a l c e l l prostacyclin production, suggest a p o t e n t i a l , h i t h e r t o unrecognized,mechanism f o r BT c o r r e c t i o n i n hemostatic disorders. -a n t i p l a t e l e t~~~)~b n e r r e r r c w a x p t i h l e w i t h~ A l l p t i f n t s a r e~t l y i n~ mrrcE*iretraatrcent.FCprth?total.
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tomxh103~109/t.0llycressekdarelaps(platel e t a m t l 8 x l 8~) . . m i s~c n~1 4 a f~~o n 2 n g / l a 3 / d prehiEaed resp-dd toan % to411gAq/dwithin5Fhys. W s z i s e e i a s k x i c i t y w s~~f c r d @ t g a i n r a n 3 i r g h 3 -l B ( m 6 % ) a r d Desmopressin (l-deamin0-8-d-arg%ne vasopressin; DDAVP) r es u l t s i n a t r a n s i e n t i n c r e a s e i n a l l F VIII components (VIII:C, VIIIR:Ag, V1IIR:Cof) i n normal s u b j e c t s a s well a s i n those with mild hemophilia A and von Willebrand's d i s e a s e (vWD). In add i t i o n , t h i s s y n t h e t i c agent e f f e c t s a t r a n s i e n t normalization of t h e bleeding time (BT) i n persons with vWD type I , and p a r t i a l c o r r e c t i o n i n type I I a . W e have given desmopressin t o 25 i n d iv i d u a l s undergoing surgery (14) o r e x t r a c t i o n of permanent t e e t h (11). Three s u b j e c t s had moderate hemophilia A while 22 had vWD type I. Desmopressin was given i n a dosage of 0.3 ug/kg, I.V., 30-45 min. p r i o r t o surgery. Those undergoing o r a l surgery were a l s o given EACA, 300 mgm/kg/day f o r 7-10 days. Hemostasis was maintained i n a l l 25 s u b j e c t s and none required blood products. Desmopressin appears t o be a s a f e and e f f e c t i v e a l t e r n a t i v e t o t h e use of blood products i n c e r t a i n i n d i v i d u a l s with mild-mode r a t e hemophilia A and vWD. P a t i e n t s e l e c t i o n should be made on t h e b a s i s o f 1) t h e p a t i e n t ' s usual b a s e l i n e F VIII l e v e l , 2 ) n a t u r e and e x t e n t of surgery t o be done, 3) type of vWD ( i . e . appropriate t e s t s should be done t o exclude vWD types I I b and 111), and 4) response t o a t e s t dose of desmopressin. Desmop r e s s i n i s p a r t i c u l a r l y u s e f u l f o r s u r g i c a l procedures i n which it i s a n t i c i p a t e d t h a t a r e l a t i v e l y short-term normalization of F VIII and BT w i l l s u f f i c e . I f r e p e t i t i v e doses of desmopressin a r e given, one must be aware of tachyphylaxis, a s well a s t h e p o s s i b i l i t y ( a l b e i t s l i g h t ) of hyponatremia and f l u i d overload.
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HYPERACTIVE PLATELETS ASSOCIATED WITH STROKE IN CHILDREN. I n d i r a Warrier and Michael Nigro.
(Spon.
b y Jeanne Lusher,)
Wayne S t a t e Univ. School o f Medicine, Children' s Hospital of ~i c h i -g a n D e t r o i t .
W e have i n v e s t i g a t e d p l a t e l e t a c t i v i t y i n 13 children (mean age 11 y r s . ) who had one o r more episodes of unexplained s t r o k e , with arteriograms revealing medium s i z e a r t e r i a l occlusions. Six c h i l d r e n had no a s s o c i a t e d r i s k f a c t o r s while 7/13 had one (migraine, hyperlipidemia, m i t r a l valve prolapse, o r a l contrac e p t i v e s ) . P l a t e l e t a c t i v i t y was assessed using e l e c t r o n microscopy (whole blood TEM p l a t e l e t function t e s t ) and p l a t e l e t aggregometry. The TEM p l a t e l e t function t e s t showed p l a t e l e t hyp e r a c t i v i t y i n 11 of 13 s u b j e c t s , with a marked s h i f t from round o r a b o r t i v e forms t o spread forms and i n c r e a s e i n spontaneous p l a t e l e t aggregates. --~o u n d /~b o r t . Dendritic Spread Aggregates Norma1 (100) 10.2 + 8.5 80.5+ 6.2 9 . 7 + 5.7 <50 P a t i e n t s ( l 3 ) 7.695 6.5
